CDiddy, the reason why I think this situation is different from the previous EUAs is that this time around the FDA has little, if any, credibility. Therefore, all of our ducks better be in a row in order to get the public to trust Leronlimab from the get-go (the boy who cried wolf syndrome). Plus, because of the FDA's lack of credibility there is an additional challenge in getting public trust immediately for Leronlimab because it was a phase 2 trial with less than 100 patients. Hence, I truly believe that the delay bodes well for a Leronlimab EAU coming imminently.